Analysts are weighing in on how Intrexon Corp (NYSE:XON), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 3 analysts, with 2 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.
For the current quarter, the 8.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.24 a share, which would compare with $-0.37 in the same quarter last year. They have a high estimate of $-0.12 and a low estimate of $-0.37. Revenue for the period is expected to total nearly $53.83M from $44.89M the year-ago period.
For the full year, 8.00 Wall Street analysts forecast this company would deliver earnings of -1.30 per share, with a high estimate of $-0.94 and a low estimate of $-1.68. It had reported earnings per share of $-0.76 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $207.44M versus 173.60M in the preceding year.
The analysts project the company to maintain annual growth of around -67.40% percent over the next five years as compared to an average growth rate of 25.76% percent expected for its competitors in the same industry.
Among the 8 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for XON is $45.50 but some analysts are projecting the price to go as high as $65.00. If the optimistic analysts are correct, that represents a 158 percent upside potential from the recent closing price of $25.20. Some sell-side analysts, particularly the bearish ones, have called for $29.00 price targets on shares of Intrexon Corp (NYSE:XON).
In the last reported results, the company reported earnings of $-0.37 per share, while analysts were calling for share earnings of $-0.04. It was an earnings surprise of -825.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; RheoSwitch inducible gene switch; Cell Systems Informatics; AttSite Recombinases; Protein Engineering; antibody discovery; LEAP processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor altering chemical or antioxidant additives; and commercial aquaculture products. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.